e Francisella philomiragia is a very uncommon pathogen of humans. Diseases caused by it are protean and have been reported largely in near-drowning victims and those with chronic granulomatous disease. We present a case of F. philomiragia pneumonia with peripheral edema and bacteremia in a renal transplant patient and review the diverse reports of F. philomiragia infections. CASE REPORTA 63-year-old female from Indiana presented to an Indianapolis hospital with worsening shortness of breath, nonproductive cough, and increasing bilateral peripheral edema. The patient was afebrile, normotensive, and normocardic but was tachypnic (40 bpm) and denied having fevers, chills, or other symptoms of an infectious process while at home. Significant medical history obtained at the time of presentation included a renal transplant secondary to polycystic kidney disease 14 years prior for which she receives chronic immunosuppressive therapy (tacrolimus and prednisone). The patient did not report recent travel outside Indiana, exposure to wild animals or recreational water sources, or exposure to sick individuals. Because of the possibility of acute transplant rejection, the patient was admitted to the intensive care unit for extensive evaluation. A chest X-ray performed at the time of admission revealed bilateral perihilar and upper-lobe infiltrates consistent with bilateral bronchopneumonia, prompting the collection of a set of blood cultures from the left arm and of another set from the right arm and initiation of empirical broad-spectrum antimicrobial therapy with vancomycin and piperacillin-tazobactam. Aside from blood cultures, no other microbiology testing was performed. Laboratory studies conducted at the time of admission revealed leukocytosis (11,600 cells/l) with 93% neutrophils, anemia (3.32 million cells/l), kidney failure (elevated levels of urea nitrogen [48 mg/dl] and creatinine [3.70 mg/dl]), and hyperglycemia (127 mg of glucose/dl). Elevated levels of procalcitonin (1.86 ng/ml), hematuria (25 cells/l), and proteinuria (500 mg/ dl) were also noted. Because of the possibility of acute-on-chronic kidney disease, a renal biopsy was subsequently performed, and it revealed acute allograft rejection.Following approximately 24 h of incubation in a continuousmonitoring blood culture instrument (BD Bactec 9240; BD Diagnostic Systems, Sparks, MD), the aerobic bottles from both sets of blood cultures signaled positively. Gram stains of broth from both bottles revealed pleomorphic, Gram-negative coccobacilli (Fig. 1A). Subcultures of the blood culture broth grew medium-sized (ϳ5-mm diameter), glossy, convex colonies resembling a member of the Enterobacteriaceae on sheep blood and chocolate agars after 48 h of incubation at 35°C in 5% CO 2 . A Gram stain of the colonies revealed organisms with morphologies identical to those seen in the blood culture broth smear. The isolate tested positive for cytochrome oxidase and catalase. Together, these observations ruled out possible select agents, including Francisella tularensis a...
One hundred seventy-eight patients were enrolled in a placebo-controlled trial to evaluate three interferon-alpha preparations administered parenterally for the treatment of condyloma acuminatum. When all interferon groups were combined and compared with placebo, interferon recipients had greater rates of complete, 75%, 50%, and 25% lesion resolution than did placebo recipients (P = .21, P = .14, P = .02, and P = .02, respectively). Rates of lesion resolution were higher among women than among men, and women were more likely than men to respond to interferon. Virologic measurements in paired lesion biopsies did not correlate with interferon treatment or disease outcome. Although interferon toxicity was observed frequently, no participant withdrew from the study because of side effects, and dosage alterations were not required. Parenterally administered interferon-alpha is more effective than placebo in treating condyloma acuminatum, although rates of complete response are low. Different regimens, including combination therapy, should be evaluated for treatment of this common sexually transmitted disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.